Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-12-20Clinical Trial Update: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL [Phase 1, Phase 2]
Phase 1/2 study evaluating venetoclax with chemotherapy in B-cell non-Hodgkin lymphoma and diffuse large B-cell lymphoma has completed with …
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial of RFT5-dgA immunotoxin for relapsed or refractory cutaneous T-cell lymphoma (a form of non-Hodgkin lymphoma) has been termina…
-
FDA approval · 2018-12-11FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)
The FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc.
-
CLINICAL_TRIALS trial_result · 2018-11-21Clinical Trial Update: Reduced Intensity Double Umbilical Cord Blood Transplantation [Phase 2]
Phase 2 results for reduced-intensity double umbilical cord blood transplantation were completed and results posted in 2018. The study evalu…
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial investigating irinotecan in patients with recurrent or refractory non-Hodgkin's lymphoma has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial update on combination chemotherapy for intermediate-grade or immunoblastic non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-11-08Clinical Trial Update: GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant [NA]
Clinical trial update on GVHD prophylaxis with post-transplant cyclophosphamide in patients with renal insufficiency receiving matched relat…
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating Rituximab, Cyclophosphamide, and Pegfilgrastim in patients with leukemia or non-Hodgkin's lymphoma has c…
-
CLINICAL_TRIALS trial_result · 2018-11-01Clinical Trial Update: R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial [Phase 2]
Phase 2 trial update for R-BMD in refractory or relapsed lymphoma (GELTAMO), completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-10-30Clinical Trial Update: A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase II trial evaluating paclitaxel and topotecan with Filgrastim-SD/01 support in relapsed and refractory aggressive non-Hodgkin's lymphom…
-
CLINICAL_TRIALS trial_result · 2018-10-25Clinical Trial Update: Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial investigating azacitidine and rituximab-GDP immunochemotherapy for relapsed/refractory diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2018-10-23Clinical Trial Update: Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL [Phase 2]
Phase 2 trial evaluating VELCADE (bortezomib) and Rituxan (rituximab) as front-line therapy for low-grade non-Hodgkin's lymphoma has complet…
-
FDA approval · 2018-10-16FDA Approved: CARMUSTINE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved the original ANDA for Carmustine (BiCNU) submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2018-09-28FDA Approved: BUSULFEX — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for Busultex (busulfan) filed by Otsuka America Pharmaceutical, Inc. The action updates the labeling…
-
CLINICAL_TRIALS trial_result · 2018-09-25Clinical Trial Update: R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial of R-ICE and high-dose cyclophosphamide with PET/CT for diffuse large B-cell non-Hodgkin's lymphoma was terminated; results ar…
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy [Phase 2]
Phase 2 trial update for ADI-PEG 20 in adults with non-Hodgkin's lymphoma who failed prior therapy completed.
-
FDA approval · 2018-09-11FDA Approved: CARMUSTINE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved Carmustine as an original ANDA for Zydus Pharmaceuticals USA Inc., authorizing a generic Carmustine formulation. The drug is us…
-
CLINICAL_TRIALS trial_result · 2018-09-10Clinical Trial Update: PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin [Phase 3]
Phase 3 trial PRELUDE studied daily enzastaurin for prevention of relapse in non-Hodgkin lymphoma; status completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial evaluating brentuximab vedotin in relapsed/refractory CD30-positive non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial investigating rituximab, temozolomide, and methylprednisolone for recurrent primary CNS non-Hodgkin's lymphoma; the s…
-
CLINICAL_TRIALS trial_result · 2018-08-27Clinical Trial Update: Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
A completed clinical trial comparing Iodine-131 tositumomab with Yttrium-90 ibritumomab tiuxetan for treating non-Hodgkin's lymphoma; result…
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis [Phase 2]
Phase II study evaluating the combination of Rituximab and DepoCyte in patients with primary cerebral non-Hodgkin lymphoma and systemic diff…
-
CLINICAL_TRIALS trial_result · 2018-08-21Clinical Trial Update: A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy [Phase 3]
Phase 3 trial ofInotuzumab Ozogamicin plus Rituximab for relapsed/refractory aggressive non-Hodgkin lymphoma in patients unsuitable for high…
-
CLINICAL_TRIALS trial_result · 2018-08-17Clinical Trial Update: Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating combination chemotherapy followed by bone marrow or stem cell transplantation in refractory Hodgkin's dise…
-
CLINICAL_TRIALS trial_result · 2018-08-09Clinical Trial Update: Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 2]
Phase 2 trial assessing ofatumumab and bendamustine followed by maintenance ofatumumab for rituximab-relapsed indolent B-cell non-Hodgkin's …